Swiss National Bank Has $1,041,000 Position in Xencor Inc. (XNCR)
Swiss National Bank increased its stake in shares of Xencor Inc. (NASDAQ:XNCR) by 13.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 54,800 shares of the biopharmaceutical company’s stock after buying an additional 6,400 shares during the period. Swiss National Bank owned 0.13% of Xencor worth $1,041,000 as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. UBS Asset Management Americas Inc. increased its position in shares of Xencor by 5.0% in the first quarter. UBS Asset Management Americas Inc. now owns 14,800 shares of the biopharmaceutical company’s stock valued at $199,000 after buying an additional 700 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in Xencor by 5.1% in the first quarter. Metropolitan Life Insurance Co. NY now owns 21,213 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 1,026 shares during the period. Strs Ohio boosted its stake in Xencor by 301.1% in the second quarter. Strs Ohio now owns 36,500 shares of the biopharmaceutical company’s stock valued at $693,000 after buying an additional 27,400 shares during the period. California State Teachers Retirement System boosted its stake in Xencor by 11.9% in the second quarter. California State Teachers Retirement System now owns 67,434 shares of the biopharmaceutical company’s stock valued at $1,281,000 after buying an additional 7,167 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in Xencor during the first quarter valued at approximately $1,303,000. Hedge funds and other institutional investors own 67.44% of the company’s stock.
Shares of Xencor Inc. (NASDAQ:XNCR) traded up 0.41% on Tuesday, reaching $24.68. The company’s stock had a trading volume of 87,805 shares. The stock has a market cap of $1.01 billion, a PE ratio of 26.23 and a beta of 2.10. Xencor Inc. has a 12-month low of $9.89 and a 12-month high of $26.50. The firm has a 50 day moving average price of $22.77 and a 200-day moving average price of $17.17.
Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $1.13 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $1.31. The firm earned $66 million during the quarter, compared to analyst estimates of $7.43 million. Xencor had a return on equity of 22.53% and a net margin of 39.07%. Equities research analysts expect that Xencor Inc. will post $0.72 EPS for the current year.
Several equities research analysts recently commented on the company. Leerink Swann reaffirmed an “outperform” rating and set a $18.00 price objective on shares of Xencor in a research report on Wednesday, June 29th. Canaccord Genuity reaffirmed a “buy” rating on shares of Xencor in a research report on Tuesday, June 28th. Piper Jaffray Cos. assumed coverage on Xencor in a research report on Tuesday. They set an “overweight” rating on the stock. Zacks Investment Research cut Xencor from a “buy” rating to a “hold” rating in a research report on Wednesday, August 31st. Finally, Wedbush reaffirmed an “outperform” rating and set a $27.00 price objective on shares of Xencor in a research report on Monday, September 12th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $23.50.
In related news, insider Edgardo Baracchini, Jr. sold 10,000 shares of the company’s stock in a transaction dated Wednesday, September 28th. The stock was sold at an average price of $25.35, for a total transaction of $253,500.00. Following the transaction, the insider now directly owns 10,000 shares of the company’s stock, valued at approximately $253,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP John R. Desjarlais sold 5,905 shares of the company’s stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $20.00, for a total value of $118,100.00. The disclosure for this sale can be found here. 4.03% of the stock is owned by insiders.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.
Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor Inc. (NASDAQ:XNCR).
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.